老年人使用抗胆碱能药物的情况。
Use of antimuscarinics in the elderly.
作者信息
Patel Bhavin, Bavendam Tamara, Badlani Gopal
机构信息
Wake Forest University Baptist Medical Center, Winston-Salem, NC, USA.
出版信息
ScientificWorldJournal. 2009 Jun 12;9:459-65. doi: 10.1100/tsw.2009.55.
Abstract
Overactive bladder (OAB) is a common, costly, and treatable condition in older persons. There is a wide array of available antimuscarinics for the treatment of these conditions; however, their side effect profile and the limited number of studies that evaluate their effect in the elderly curb their use. This review article focuses on OAB and its treatment, with special attention to the use of antimuscarinics in the elderly.
摘要
膀胱过度活动症（OAB）在老年人中是一种常见、代价高昂但可治疗的病症。有多种抗毒蕈碱药物可用于治疗这些病症；然而，它们的副作用情况以及评估其对老年人疗效的研究数量有限，限制了它们的使用。这篇综述文章聚焦于膀胱过度活动症及其治疗，特别关注抗毒蕈碱药物在老年人中的使用。
相似文献
1
Use of antimuscarinics in the elderly.
ScientificWorldJournal. 2009 Jun 12;9:459-65. doi: 10.1100/tsw.2009.55.
2
Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin.
Clin Interv Aging. 2008;3(3):503-9. doi: 10.2147/cia.s3414.
3
Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder.
Expert Opin Pharmacother. 2007 Mar;8(4):511-23. doi: 10.1517/14656566.8.4.511.
4
Pharmacologic management of overactive bladder.
Clin Interv Aging. 2007;2(3):337-45.
5
Treatment of overactive bladder in the aging population: focus on darifenacin.
Clin Interv Aging. 2006;1(4):309-16. doi: 10.2147/ciia.2006.1.4.309.
6
7
Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
Neurourol Urodyn. 2009;28(5):416-22. doi: 10.1002/nau.20672.
8
Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.
Arch Gerontol Geriatr. 2017 Mar-Apr;69:77-96. doi: 10.1016/j.archger.2016.11.006. Epub 2016 Nov 14.
9
Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy.
Int J Clin Pract. 2008 Nov;62(11):1664-74. doi: 10.1111/j.1742-1241.2008.01893.x. Epub 2008 Sep 22.
10
Current management and future perspectives of overactive bladder (OAB) pharmacotherapy.
Acta Pol Pharm. 2011 Nov-Dec;68(6):807-21.
引用本文的文献
1
Management of urinary incontinence.
P T. 2012 Jun;37(6):345-361H.
2
Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study.
BMC Urol. 2012 Jul 26;12:19. doi: 10.1186/1471-2490-12-19.
Zotero 插件